Congratulations to Totus Medicines for raising a $66M Series B led by DCVC Bio
Congratulations to Totus Medicines for raising a $66M Series B led by DCVC Bio
Congratulations to Totus Medicines for raising a $66M Series B led by DCVC Bio
Congratulations to Totus Medicines for raising a $66M Series B led by DCVC Bio
FILTER BY SECTOR
FILTER BY PARTNER
FILTER BY STAGE
FILTER BY IMPACT
FILTER BY FUNDS
FILTER BY NETWORK
FILTER BY DOMAIN
FILTER BY SKILlS
...
We believe in Khosla's Instigator Hypothesis: individuals scaling world-changing technology will solve the largest problems in the world. For example, 12-15 entrepreneurs creating the right companies is all it will take to solve the climate crisis.
We are a research-driven venture capital firm that invests as early as possible into the “best ideas in impact.” Too much of venture capital has gone into “backyard problems” rather than the grand global challenges.
We exist to fund and support founders working on the hardest problems in the world.
AS OF Q4 2023
Platform to rapidly design covalent drugs and cure new illnesses.
Converts waste biomass into fast pyrolysis, high carbon bio-oil.
Removes CO2 and turns it into carbon-zero gasoline, diesel, and jet fuel.
Build remote engineering teams with the world’s top talent.
ESG investing products that reflect the true impact of your investments.
Clean, sustainable cosmetics.
We partner early. We are comfortable with the rough imperfections of start-ups. As a solo GP with 39+ venture partners, we are highly responsive but also have the broad-based experience to fully support world-changing entrepreneurs.
Bloomberg April 22, 2024
Washington Post April 21, 2024
Canary Media April 18, 2024
CNBC April 8, 2024
Robb Report April 5, 2024